Table 1.
Participant characteristics.
| Baseline | ||
|---|---|---|
| TRAD (n = 9) | STAIR (n = 9) | |
| Sex (M/W) | (8/1) | (8/1) |
| Age (years) | 61 ± 8 | 62 ± 6 |
| Height (cm) | 170 ± 12 | 175 ± 6 |
| Body mass (kg) | 89 ± 12 | 90 ± 11 |
| BMI (kg/m2) | 29.7 ± 4.1 | 29.8 ± 3.3 |
| Resting SBP (mmHg) | 116 ± 18 | 113 ± 17 |
| Resting DBP (mmHg) | 71 ± 10 | 78 ± 7 |
| Resting HR (bpm) | 68 ± 10 | 74 ± 12 |
| Clinical | ||
| STEMI (n, %) | 1 (11.1) | 2 (22.2) |
| NSTEMI (n, %) | 5 (55.6) | 5 (55.6) |
| Angina (n, %) | 2 (22.2) | 2 (22.2) |
| PCI (n, %) | 5 (55.6) | 7 (77.8) |
| CABG (n, %) | 4 (44.4) | 2 (22.2) |
| Time since event (weeks) | 7.6 ± 4.2 | 8.6 ± 5.3 |
| Medications | ||
| Beta-blockers (n, %) | 7 (77.8) | 9 (100) |
| ACE inhibitors (n, %) | 7 (77.8) | 6 (66.6) |
| ASA (n, %) | 9 (100) | 9 (100) |
| Lipid lowering (n, %) | 9 (100) | 9 (100) |
| Metformin (n, %) | 2 (22.2) | 1 (11.1) |
| CVD risk factors | ||
| Previous smoking history (n, %) | 3 (33.3) | 2 (22.2) |
| T2DM (n, %) | 3 (33.3) | 1 (11.1) |
| Hypertension (n, %) | 8 (88.9) | 6 (66.7) |
| Previous cardiac event (n, %) | 5 (55.6) | 0 (0) |
| Dyslipidemia (n, %) | 8 (88.9) | 6 (66.7) |
Data are mean ± SD. BMI, body mass index; BP, blood pressure; HR, heart rate; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous intervention; CABG, coronary artery bypass graft; ACE, angiotensin-converting enzyme; ASA, acetylsalicylic acid; CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus.